Figure 8B,C clearly show that while liposomal doxorubicin significantly decreased the frequency of CD8+, treatment with GE11-Lipo CD73 siRNA could not decrease the frequency of CD8+ T cells at tumor site. The gene discussed is CD8A; the disease is neoplasm.